Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Gyre Therapeutics ( (GYRE) ) is now available.
At a March 10, 2026 investor conference, Gyre Therapeutics outlined expectations that its Hydronidone (F351) liver fibrosis program could generate approximately $400 million to $600 million in revenue within five years, while its ETUARY lung fibrosis franchise may sustain around $100 million in sales if generic competition remains limited. The company projected net margins of 20% to 25% on commercial products, highlighted that 30% to 40% of current lung fibrosis revenue comes from rheumatoid disease patients whose conditions progress to lung fibrosis, and signaled potential upside from off-label MASH use and further rheumatology-driven expansion.
Gyre’s affiliate Cullgen reported that its TRK degrader CG001419 showed validated safety at 400 mg in an Australian cohort and is now enrolling a Phase 2 U.S. pain trial at doses expected to achieve about 95% TRK degradation. The company emphasized that CG001419’s short-course dosing is designed to address NGF-class joint toxicity concerns, and noted that its degrader antibody conjugates demonstrate 10- to 100-fold higher potency than standalone degraders, with roughly half of Cullgen’s R&D staff focused on DAC conjugation and a deep degrader library enabling internal conjugation capabilities.
The most recent analyst rating on (GYRE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Gyre Therapeutics stock, see the GYRE Stock Forecast page.
Spark’s Take on GYRE Stock
According to Spark, TipRanks’ AI Analyst, GYRE is a Neutral.
The score is primarily driven by mixed financial performance—strong margins and a low-leverage balance sheet but material cash flow weakness. Technicals are bearish with price below key moving averages and negative MACD, and valuation is stretched due to a very high P/E. These are partially offset by a positive corporate catalyst from progress toward potential China approval for Hydronidone.
To see Spark’s full report on GYRE stock, click here.
More about Gyre Therapeutics
Gyre Therapeutics, Inc. is a biopharmaceutical company focused on therapies for liver and lung fibrosis, including its Hydronidone (F351) candidate for liver fibrosis and the commercial lung fibrosis drug ETUARY. Through its affiliate Cullgen Inc., which operates R&D campuses in Beijing and Shanghai, the company also develops targeted protein degraders and degrader antibody conjugates for pain and other indications.
Average Trading Volume: 91,896
Technical Sentiment Signal: Hold
Current Market Cap: $757.1M
See more insights into GYRE stock on TipRanks’ Stock Analysis page.